Zurich Cantonal Bank
ORIC icon

Zurich Cantonal Bank’s Oric Pharmaceuticals ORIC Stock Holding History

Zurich Cantonal Bank’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,546
Closed -$135K – 3215
2025
Q4 		$135K Buy
+16,546
New +$190K ﹤0.01% 2339

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Zurich Cantonal Bank's ORIC Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Oric Pharmaceuticals (ORIC) stake by 86% in Q2 2026, buying an estimated $120K and bringing the position to 28,682 shares worth $311K. The position accounts for ﹤0.01% of the portfolio, ranked #2168.

Zurich Cantonal Bank first reported a position in ORIC in Q1 2021 and has held it in 11 quarters since. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Zurich Cantonal Bank held 28,682 shares of Oric Pharmaceuticals worth $311K as of Q2 2026.
  • Zurich Cantonal Bank bought 13,250 Oric Pharmaceuticals shares in Q2 2026, an estimated $120K.
  • Oric Pharmaceuticals made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2168 holding.
  • Zurich Cantonal Bank first reported a position in Oric Pharmaceuticals in Q1 2021 and has held it in 11 quarters since.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.